Pan-TRK Immunohistochemistry: A Useful Diagnostic Adjunct For Secretory Carcinoma of the Breast.


Journal

The American journal of surgical pathology
ISSN: 1532-0979
Titre abrégé: Am J Surg Pathol
Pays: United States
ID NLM: 7707904

Informations de publication

Date de publication:
12 2019
Historique:
pubmed: 10 9 2019
medline: 14 4 2020
entrez: 10 9 2019
Statut: ppublish

Résumé

Secretory carcinoma is a special-type breast carcinoma underpinned by a recurrent t(12;15)(p13;q25) translocation resulting in ETV6-NTRK3 gene fusion. Immunohistochemistry (IHC) using a pan-TRK antibody has been recently shown to help identify NTRK rearrangements in other tumor types. The purpose of this study was to assess the diagnostic utility of pan-TRK IHC in secretory carcinoma of the breast. Pan-TRK IHC was performed using a rabbit monoclonal antibody on whole sections of 24 breast secretory carcinomas and tissue microarray sections of other breast carcinoma types (n=203) and histologic mimics (n=15). Cases were assessed for staining intensity and localization. The 24 patients with secretory carcinoma had a median age of 44 years and a median tumor size of 1.0 cm. ETV6 fluorescence in situ hybridization was positive in all cases tested (n=20). Twenty-three cases (95.8%) showed staining with pan-TRK, which was exclusively nuclear in 19, primarily nuclear with weak cytoplasmic staining in 3, and primarily cytoplasmic with focal nuclear staining in 1. The nuclear staining was diffuse in 17 and at least focally strong in 17. The only pan-TRK negative case was a core biopsy with limited tumor. Among the 203 nonsecretory carcinomas, 21 (10.3%) showed focal, weak nuclear staining in <5% of tumor cells and 1 (0.5%) showed focal membranous staining. All histologic mimics were negative. In conclusion, diffuse and/or at least focally strong nuclear pan-TRK staining is a sensitive and specific marker for secretory carcinoma of the breast.

Identifiants

pubmed: 31498178
doi: 10.1097/PAS.0000000000001366
doi:

Substances chimiques

Biomarkers, Tumor 0
Proto-Oncogene Proteins c-ets 0
Receptors, Nerve Growth Factor 0
Repressor Proteins 0

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1693-1700

Auteurs

Beth T Harrison (BT)

Department of Pathology, Brigham and Women's Hospital.
Harvard Medical School.

Elizabeth Fowler (E)

Department of Pathology, Brigham and Women's Hospital.
Harvard Medical School.

Gregor Krings (G)

Department of Pathology, University of California San Francisco.

Yunn-Yi Chen (YY)

Department of Pathology, University of California San Francisco.

Gregory R Bean (GR)

Department of Pathology, Stanford University School of Medicine, Stanford, CA.

Anne Vincent-Salomon (A)

Department of Pathology, Institut Curie, Paris, France.

Laetitia Fuhrmann (L)

Department of Pathology, Institut Curie, Paris, France.

Sandra E Barnick (SE)

Department of Pathology, Memorial Hospital West, Pembroke Pines, FL.

Beiyun Chen (B)

Department of Pathology, Mayo Clinic and Foundation, Rochester, MN.

Elizabeth M Hosfield (EM)

Department of Pathology, Kaiser Permanente San Francisco Medical Center, San Francisco.

Jason L Hornick (JL)

Department of Pathology, Brigham and Women's Hospital.
Harvard Medical School.

Stuart J Schnitt (SJ)

Department of Pathology, Brigham and Women's Hospital.
Harvard Medical School.
Dana-Farber Cancer Institute, Boston, MA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH